NCT04153422View on ClinicalTrials.gov

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

August 27, 2027

Study Completion Date

February 28, 2028

Conditions
Small Fiber NeuropathyAutoimmune Small Fiber NeuropathyInflammatory PolyneuropathyImmune-Mediated Neuropathy
Interventions
DRUG

Panzyga IVIG

Immune Globulin Infusion 10% (Human)

DRUG

Placebo

0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.

Trial Locations (1)

60201

RECRUITING

Endeavor Health, Evanston

Sponsors

Lead Sponsor

Endeavor Health
All Listed Sponsors
collaborator

Octapharma USA, Inc.

UNKNOWN

lead

Endeavor Health

OTHER